^
    Apply
    Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations (NCT04521686)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    10/16/2020
    Primary completion :
    07/17/2023
    Completion :
    05/01/2025
    IDH1 • IDH2
    |
    IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • LY3410738
    Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (NCT04603001)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    12/01/2020
    Primary completion :
    07/03/2023
    Completion :
    05/01/2025
    IDH1 • IDH2
    |
    IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    Venclexta (venetoclax) • azacitidine • LY3410738